Comparison of Cardiovascular Risks following Smoking Cessation Treatments Using Varenicline vs. NRT among Schizophrenic Smokers
Archives of Psychiatry and Mental Health · 2017
DOI: 10.29328/journal.apmh.1001001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Psychiatry and Mental Health, 2017. Verfasst von I-Hsuan Wu und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Schizophrenic patients have a lot higher smoking rates when compared to people in the general population. A variety of pharmaceutical cessation aids are available, which include nicotine replacement therapy (NRT), Bupropion SR, and Varenicline. Our objective was to assess which cessation medication would have lower risks in developing risk factors of cardiovascular diseases.
Methods
A population-based retrospective cohort study was conducted using the General Electric (GE) electronic medical record database (1995-2011). The cohort consisted of patients with a diagnosis of schizophrenia or schizoaffective disorder (ICD-9 code 295.00-295.99) and who had newly initiated use of any smoking cessation medication. We excluded our cohort who (1) were not prescribed atypical antipsychotics and (2) already had diagnosis of diabetes, hyperlipidemia or hypertension prior to index date. Follow up period was from 12 weeks onwards index date up to one year. The hazard ratio of developing cardiovascular risks was assessed using Cox proportional hazards regression model after controlling for other covariates.
Results
A total of 580 patients were included in our cohort. Among those, nearly half (n=276, 47.59%) developed one or more criteria of the metabolic syndromes. We found that smokers who were prescribed NRT were less likely to develop metabolic syndromes as compared to those who were prescribed Varenicline.
Conclusions
Physicians are advised to carefully weigh the risks against the benefits before prescribing cessation medications since risks for metabolic syndromes were found to be very high. Healthcare providers should monitor patients’ lab data regularly as this minority population is under higher risks.
Zitieren
APA
Wu, I., Chen, H., Bordnick, P., Essien, E. J., Johnson, M., Peters, R. J., & Abughosh, S. (2017). Comparison of Cardiovascular Risks following Smoking Cessation Treatments Using Varenicline vs. NRT among Schizophrenic Smokers. Archives of Psychiatry and Mental Health. https://doi.org/10.29328/journal.apmh.1001001
Vancouver
Wu I, Chen H, Bordnick P, Essien EJ, Johnson M, Peters RJ, et al. Comparison of Cardiovascular Risks following Smoking Cessation Treatments Using Varenicline vs. NRT among Schizophrenic Smokers. Archives of Psychiatry and Mental Health. 2017. doi:10.29328/journal.apmh.1001001
BibTeX
@article{Wu2017,
author = {Wu, I-Hsuan and Chen, Hua and Bordnick, Patrick and Essien, Ekere James and Johnson, Michael and Peters, Ronald J and Abughosh, Susan},
title = {Comparison of Cardiovascular Risks following Smoking Cessation Treatments Using Varenicline vs. NRT among Schizophrenic Smokers},
journal = {Archives of Psychiatry and Mental Health},
year = {2017},
doi = {10.29328/journal.apmh.1001001}
}
EUVIMED